Using breath analysis for quick diagnosis of respiratory diseases
Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections
This study is testing a new way to quickly diagnose respiratory diseases by analyzing the breath of patients on ventilators to see if it can help detect problems earlier.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | Oregon Health and Science University Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT06775106 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate a novel technique using mass spectrometry to analyze exhaled breath from non-COVID ICU patients on ventilation. The study will employ Orbitrap and MALDI mass spectrometry to capture and analyze proteins in breath samples, correlating these findings with existing clinical data to enhance early detection of pulmonary diseases. By focusing on ventilator-dependent patients, the study seeks to establish a rapid diagnostic tool that could be utilized in non-ICU settings for respiratory pathogen detection.
Who should consider this trial
Good fit: Ideal candidates for this study are non-COVID-19 adult patients over 18 years old who are on ventilatory support in the ICU.
Not a fit: Patients experiencing severe respiratory distress or hemodynamic instability may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could lead to faster and more accurate diagnoses of respiratory diseases, improving patient outcomes.
How similar studies have performed: While the approach is innovative, similar studies using breath analysis for disease detection have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-COVID-19 adult consented patients (\>18yo) on ventilatory support in the ICU at OHSU Exclusion Criteria: * Patients with "severe respiratory distress" as defined by arterial pO2 of \<60 mmHg on maximal FiO2 \& optimal ventilator settings * Patient with severe hemodynamic instability as defined by (a) receiving IV infusion of 2 or more pressors or inotropic medications (Levophed, vasopressin, phenylephrine, or epinephrine) \& (b) MAP of \<60 mmHg or SB \<80 mmHg
Where this trial is running
Portland, Oregon
- Oregon Health and Science University — Portland, Oregon, United States (Recruiting)
Study contacts
- Study coordinator: Laura H Nguyen, B.S.
- Email: nguyelau@ohsu.edu
- Phone: 503-418-4733
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.